{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T21:48:01Z","timestamp":1769636881549,"version":"3.49.0"},"reference-count":3,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2023.1166588","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T10:49:10Z","timestamp":1678358950000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Editorial: Advances in the treatment of chronic myeloid leukemia"],"prefix":"10.3389","volume":"13","author":[{"given":"Ahmet Emre","family":"E\u015fkazan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung H.","family":"Kok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jignesh","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Tiribelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.31408","article-title":"The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia","volume":"124","author":"Ercaliskan","year":"2018","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2019001329","article-title":"First-line imatinib vs second- and third- generation TKIs for chronic-phase CML: A systematic review and meta-analysis","volume":"4","author":"Vener","year":"2020","journal-title":"Blood Adv"},{"key":"B3","article-title":"Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy","volume":"34","author":"Breccia","year":"2020","journal-title":"A campus CML survey. Leukemia"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1166588\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T10:49:13Z","timestamp":1678358953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1166588\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":3,"alternative-id":["10.3389\/fonc.2023.1166588"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1166588","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,9]]},"article-number":"1166588"}}